Available online on 15.08.2020 at http://ajprd.com



Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-20, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited





Review Article

A Review on Anti-Stress Activity of Piper Methysticum

Ankit Sharma *, Rahul Anchariya, Chetan Dubey

Department of Pharmacology, Kota College of Pharmacy, Kota, Rajasthan, India

ABSTRACT

On the basis of study conducted on the plant *Piper methysticum* G. (Forst), Piperaceae, it was found that Kava has storage of active constituents present in its roots and rhizomes. Traditionally its root part is used to relax body and mind and promote restful sleep, therefore it is necessary to explore its importance as excellent nervine herb. Literature survey revealed that kavalactones are responsible for biological activity which include local anaesthetic, antispasmodic, Musculo-relaxant, antimycotic, sedative, anticonvulsive, analgesic, antianxiety and neuroprotective effects etc. which proves it has potent psychoactive ability but, the claim of therapeutic efficacy of the plant as an anti-stress or adaptogen yet has not been scientifically scrutinized. However, synthetic drugs are widely prescribed to reduce stress and stress induced symptoms but their soporific effect, risk of dependence and withdrawal effects limits their long-term use. Based on clinical studies Kava shows its efficacy within one week at moderate dose. Evidently, the herbal formulations claimed to enhance physical endurance; it is essential to study its safety and efficacy for its therapeutic use.

Keywords: Anti-Stress, Piperaceae, Traditional, Kava

A R T I C L E I N F O: Received 20 Jan 2020; Review Completed 27 March 2020; Accepted 02 August 2020; Available online 15 August 2020



Cite this article as:

Sharma A, Anchariya R, Dubey C, A Review on Anti-Stress Activity of Piper Methysticum, Asian Journal of Pharmaceutical Research and Development. 2020; 8(4):130-136. DOI: <u>http://dx.doi.org/10.22270/ajprd.v8i4.688</u> *Address for Correspondence:

Ankit Sharma, Department of Pharmacology, Kota College of Pharmacy, Kota, Rajasthan

INTRODUCTION

A sture always stands as a golden mark to exemplify the outstanding phenomena of symbiosis. Today about 80% of people in developing countries still relays on traditional medicine based largely on species of plants and animals for their primary health care (Chopra et al., 1956). Ancient pharmacopoeias from different regions of the world have recorded numerous herbal medicines purported to have psychotropic potential (Weigant et al., 2009). Indeed, nearly 25% of today's conventional drugs originated directly or indirectly from plants many valuable psychoactive drugs, such as yohimbine, ephedrine, tubocurarine, and galanthamine, were discovered through the study of indigenous remedies (Provino., 2010; Robinson et al., 2009; Thompson et al., 2004). Ayurvedic medicine aims to integrate and balance the body, mind, and spirit, thus, some view it as "holistic." Ayurvedic medicine also treats specific physical and mental health problems with the aim cleanse the body of substances that can cause disease, thus helping to re-establish harmony and balance (Chopra and Doiphode, 2002). According to Ayurveda Vata, the main dosha (life force), characteristics of body constitutions(prakriti), is susceptible to stress and neurological conditions, rheumatoid arthritis, heart and skin disease, which is aggravated by, fear, grief, staying up late at night, eating dry fruit, or eating habits (Mishra et al., 2001). In Ayurveda, stress and gastrointestinal disturbances are considered to be causative or excitant of a variety of disease (Singh et al., 1991). According to the report of WHO, approximately 450 million people suffer from mental or behavioural disorders like stress responsible for 12.3% of the global burden of disease, and predicted to rise up to 15% by 2020 (Bimlesh Kumar et al., 2011).

Asian Journal of Pharmaceutical Research and Development. 2020; 8(4): 130-136

PLANT PROFILE



Figure: 1 Piper methysticum F.

Taxonomical Classification

A significant data on the taxonomy of Piper methysticum (Kava)

Kingdom	Plantae – Plants
Subkingdom	Tracheobionta – Vascular plants
Super division	Spermatophyta – Seed plants
Division	Magnoliophyta – Flowering plants
Class	Magnoliopsida – Dicotyledons
Subclass	Magnoliidae
Order	Piperales
Family	Piperaceae – Pepper family
Genus	Piper L. – pepper
Species	Piper methysticum G. Forst. – kava



Figure: 2 Kava Rhizome



Figure: 3 Kava Roots

Morphological Description

Table 1: List of microscopical	characterisation of	of Kava (<mark>Piper</mark>	methysticum. F) plant.
	K		

Parts	Characteristics	Appearance	Reference
Plant	Dioecious, occasionallymonoecious, massive base (crown or short rootstock) from which several shoots arises.	2-4 m tall, woody perennialshrub, rosette appearance	(Orwa et al., 2009; Singh and Blumenthal, 1997).
Stem	Lenticle bearing, swollen nodes and prominent scars left by abscission of leaves and branches	1-3 cm (diameter), erect, green or red brown or dark purple.	(Nelson, 2000; Glover, 2007).
Leaves	Prominent and blades have 11–13 alternate veins originating at the base and 2.5 cm (1 in) long petioles (2-7 cm), margin entire and wavy, apex acute, globous to finely pubescent	Deciduous,heart shaped, 10-30 cm x 8-23 cm, stipules large	(Lebot et al., 1984; Singh, 1992).
Roots	It may eventually become a heavy knotted 8–25cm wide mass,	60cm in length and 8cm in diameter	(Muller and Komorek, 1999; Douglas, 2007).
Internodes	Uniform, mottled, speckled, striated and speckled.	short and thick, long and thin, long and thick	(Nelson, 2000; Johnston and Rogers, 2006).
Rhizomes	Massive, 2-10 kg, branched and juicy with many roots.	Blackish grey outside, whitish inside.	(PDR for Herbal Medicines, 2000; Broderick et al., 2005).
Flowers	Borne on narrow spike, inflorescence type, axillary or opposite but smaller the leaves, small asexual flower.	Sepals or petals (absent) Pendicle(1.5cm long)	(Davis and Brown., 1999; Lebot et al., 1999).
Spike	Male- numerus flowers with 2 short stamen Female- Flower with single basal ovule in an unilocular ovary topped by a stigma	3-9 cm long	(Orwa et al., 2009; Yarnell., 2007)
Fruit	A berry containing one seed.	-	(Orwa t al., 2009; Lebot et al., 1984)
Organoleptic property	Taste-pungent and numbing Odour- reminiscent of lilac Fracture-mealy and splintery	-	(PDR for Herbal Medicines., 2000)

1.2 Microscopy:

- T.S xylem- small channels with vascular bundles.
- Cross section (xylem)- narrow vessels located around the pith and alternate with large pith rays (Lebot et al., 1999; Orwa et al., 2009). Additional vessels across the pith; xylem has tracheid-like elements. Secretory canals contain a fine, brown resinous mass (Glover, 2007).
- Unpeeled rhizome has a narrow cork-layer (Singh, 1992).
- Primary bark contains rays of collenchyma, tissues, numerous resin and storage cells around the phloem (Lebot, Merlin and Linstorm, 1989).

1.3 Chemical Constituents

Fresh kava root contains on average 80% water. Dried root contains approx. 43% starch, 20% fibres, 15% kava lactones, 12% water, 3.2% sugars, 3.6% proteins, and 3.2% minerals (**Khorassani** et al., 1999).

Table- 2: List of distribution and analysis of chemical profile of Kava plants.	
---	--


Constituents	Structure	Spectroscopy	
A. Resins: Kavalavtones (arylethylene-alpha-pyrone-skeleton) (Roots and rhizomes)			
Dihydrokawain	OCH3 O O D D D D D D D D D D D D D D D D D D	HPLC-8.4 mg; GCMS32.107 m/z	
Kawain	OCH ₃	HPLC-21.6 mg; GCMS-237.0937 m/ z	
Methysticin	OCH ₃ OCH ₃	GCMS-274.0832 m/z	
Dihydromethysticin	OCH ₃	HPLC-6.3 mg; GC/QTOFMS276.0986 m/z	
Yangonin	OCH ₃ 0 0 0 0 0	UV-355-360; HPLC-9.3 mg; GC/QTOFMS258.0884	
Desmethoxyangoni n	OCH3	HPLC-11.6 mg	

B. Alkaloids: Piperidine(leaves and stem peelings)			
Pipermethystine		NMR: 1H-δ 52.4 13C- δ 53.4	
3α,4α-Epoxy-5β- pipermethystine		:13C169.2; MS: HRE IMS-m/z 303.1117, EIMS- m/z-303[M]+	
Awaine		NMR: 1H- 6.83, d, 8.2.13C -127.3 MS:HREIMS- m/z 31.1294(m/z 231.1259).	
C. Chalcone: Flavokawain (i	roots)	ical	
Flavokavain A	H ₃ CO HO OCH ₃	HPLC-14.2 mg	
Flavokavain B	HO OCH ₃	HPLC-8.2 mg	
Flavokavain C		HPLC-DAD-ESI-MS: [M-H] ⁻ at m/z 299	

1.4 Mechanism involved:

- Blockade of voltage-gated sodium channels (Piscopo, 2007).
- Enhanced interactions between ligand and corresponding receptors (e.g., amino butyric acid type A receptor) (Davies et al., 1992)
- Inhibition of enzyme activity (e.g., cyclooxygenase-2) (Anke and Ramzan, 2004).
- Decrease in cytokine release (e.g. TNF-α) (Pollastri et al., 2009).


ANTISTRESS ACTIVITY 2.1 Anoxia stress tolerance test (Pawar and Hugar., 2012)



Immediately remove from the vessel and resuscitate (if needed). Delay in removal of animal may lead to death.

Record the time duration of entry of animal into the vessel and appearance of the first convulsion – Anoxia tolerance time.

2.1.2 Chronic cold restrained stress test (Bimlesh Kumar et al., 2010)




Continue the procedure for 10 days after introducing the drug on 11th day; collect the blood sample through retro orbital puncturing under light ether anaesthesia and biochemical parameters.

2.1.3 Forced swim test (Zomkowski et al., 2006)

A polypropylene open cylindrical container (diameter 10 cm, height 25 cm), containing 15 cm of water at 25 ± 1 °C.

on the 8th day of dosing allow rats to swim till complete exhaustiontake the end point when animal ceases struggling and remained floating motionless in the water, making only those movements necessary to keep itshead above water.

Animal said to be immobilized, the totalduration of immobility during the 6-min test was scored. The duration of immobility was recorded and decrease in the duration of immobility during the FST was taken.





Place the mouse inside a 3-sided cubicle

Suspend its tail from a hanger attach to a linear load cell that measures activity

Acclimate to testing conditions for at least 1 min, to account that animal are uniformly active during this time

Measurements are taken for 7 min,

exclude the mice that climb their tail or fell off the hanger from analysis Calculate the percent immobility by determining the time spent immobile during the last 6 min of the test, and report percent of time (on a scale of 0-1) spent immobile.

REFERENCES:

- 1. Almedia RN, Navarro SD and Barbosa-Filho. Plants with central analgesic activity. *Phytomedicine*, 2001; 8(4):310-322.
- Anke J, Ramzan I.. Review: Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). *Journal of Ethnopharmacology*, 2004; 93:153–160.
- Austin A, Elsie CS. and Thirugnanasambantham.P. Evaluating the clinical efficacy of polyherbal formulation Arogh Plus on stress – A Randomized Clinical Study. *Journal of Stress Physiology & Biochemistry*, 2011; 7(1):66-78.
- Azmathullah S et al., 2005. Seyle.H- The Evaluation of stress concept, pp. 692.http://www.stress.org/management-tips
- Backhauss C. and Krieglstein J., Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. *European Journal of Pharmacolology*, 215, pp. 265-269.
- Bansal N and Yadav S., Stress the Stress. International Journal of Pharmaceutical and Biological Sciences, 2010; 1(4).
- Bhattacharya K and Ghosal S., Experimental evaluation of the antistress activity of an herbal formulation, zetress. *Journal of Natural Remedies*, 2000; 1:1 -7.
- Bilia AR, Scalise L, Bergonzi MC, Vincieri FF., Analysis of kavalactones from Piper methysticum (kava-kava). *Journal of Chromatography B*, 2004; 812(1-2):203-14.
- Bimlesh Kumar, Shakti Puri et al., Comparative pharmacological evaluation of adaptogenic activity of Holoptelea integrifolia and with aniasomnifera. *International Journal of Drug Development & Research*, 2011; 3(1).
- 10. Broderick M and Teresa Dodd-Butera, 2005. Kava. Elsevier Inc
- Chaudhuri A., Pathophysiology of stress: a review. International Journal of Research and Review. 2019; 6(5):199-213.
- 12. Castleman M., 2001. The New Healing Herbs 2nd ed. Emmaus, Pennsylvania: Rodale Press.

- 13. Chopra A, Doiphode VV., Ayurvedic medicine—core concept, therapeutic principles, and current relevance. *Medical Clinics of North America*, 2001; 86(1):75-88.
- Chopra RN, Nayar SI and Chopra IC., 1956. "In Glossary of Indian medicinal plants", National Institute of Science Communication Council of Scientific & IndustrialResearch New Delhi, India, pp. 207.
- Davies LP, Drew CA, Duffield P, et al., "Kava pyrones and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain". *Annual Review of Pharmacology and Toxicology*, 1992; 71:120-6.
- 16. Davis RI., Brown JP., 1999. Kava (Piper methysticum) in the South Pacific: its importance, methods of cultivation, cultivars, diseases and pests, *Australian Centre for International Agricultural Research* ACIAR Technical Reports Series No. 46, pp.32.
- Emser W, Bartylla K., Improvements in quality of sleep: effect of kava extract WS 1490 auf das Schlafmusterbei Gesunden. *Neurologie/Psychiatrie*, 1991; 5:636–642.
- Gleitz J, Friese J, Beile A, et al., Anticonvulsive action of (+/-)kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. *Europeon Journal of Pharmacology*, 1996; 315:89-97.
- 19. Glover DD., 2007. Kava. Forensic Science and Medicine, pp. 27-40.
- Jamieson DD, Duffield PH., The antinociceptive actions of kava components in mice. *Clinical and Experimental Pharmacology and Physiology*, 1990; 17:495-507.
- Keller F, Klohs MW., 1963. A review of the chemistry and pharmacology of the constituents of Piper methysticum. *Lloydia* 26, pp. 1-15.
- Lasme P, Davrieux F, Montet D, Lebot V., Quantification of kavalactones anddetermination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality

control in vanuatu. *Journal for Agricultraland Food Chemistry*, 2008; 56(13):4976-81.

- Lebot V, Sim'eoni P., 2004. "Is the quality of kava (Piper methysticum Forst. f.) responsible for different geographical patterns?" *Ethnobotany Research Applications*, 2, pp. 19-28.
- Lebot V, Merlin M, and Lindstrom L., 1997. Kava: The Pacific Elixir. Yale University Press 10, New Haven, CT.
- Lebot V, Dennis J. McKenna, Ed Johnston, Qun Yi Zheng and Doug McKern., Morphological, phytochemical, and genetic variation in Hawaiian cultivars of 'Awa (Kava, Piper methysticum, piperaceae). *Economic Botany*, 1999; 53:407-418.
- Mishra L, Singh BB, Dagenais S., Healthcare and disease management in Ayurveda. *Alternative Therapies in Health and Medicine*, 2001; 7(2):44-50.
- 27. Mishra L, Singh BB, Dagenais S., Ayurveda: a historical perspective and principles of the traditional healthcare system in India. *Alternative Therapies in Health and Medicine*, 2001; 7(2):36-42.
- Naik SR, Azmathulla S and Hule AK., Evaluation of adaptogenic activity profile of herbal formulation. *Indian Journal of Experimental Biology*, 2006; 44:574-579.
- Nelson SC., 2000. 'Awa dieback in Hawaii. University of Hawaiat Mānoa, College of Tropical Agriculture and Human Resources, PD-18. http://www2.ctahr.hawaii.edu/oc/freepubs/pdf/PD-18.pdf.

Asia

- Neuhaus W, Ghaemi Y, Schmidt T and Lehmann E., Treatment of perioperative anxiety in on sleep patterns in healthy people. *TW NeurologiePsychiatrie*, 1991; 5:636-642.
- Orwa et al., 2009. Piper methysticumPiperaceae G. Forster. Agroforestry Database 4.0
- Panossian A, Wikman G., Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. *Current Clinical Pharmacology*, 2009; 4:198–219.
- Panossian AG., 2003. Adaptogens-Tonic Herbs for Fatigue and Stress. *Alternative & Complementary Therapies*, pp. 2003; 327-331.
- Rouse J. Kava: A South Pacific Herb for Anxiety, Tension, and Insomnia. *Clinical Nutrition Insights Inc*, 1998; 6:10.
- Seyle.H., The evolution of stress concept. American Scientist, 1973; 61:693-699.
- 36. Singh YN, Singh NN. 2002. Therapeutic potential of kava in the treatment of anxiety disorders. *CNS Drugs*, 2002; 16(11):731-43.
- Wheatley D., 2001. Kava and Valerian in the treatment of stressinduced insomnia. *Phytotherapy Research*, 2001; 15(6):549-551.
- 38. Yarnell E., 2007. Piper methysticum G Forster (Kava), Piperaceae and related species.